News Pfizer targets $2.5bn more in cost savings Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.
Oncology ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.
News Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early... Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial.
Oncology Closing the global evidence gap in oncology, with Flatiron H... Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.
